Related Experiment Video
Updated: Feb 6, 2026

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting
Published on: December 9, 2022
Dose-dependent reversal of KCC2 hypofunction and phenobarbital-resistant neonatal seizures by ANA12
B M Carter1, B J Sullivan1, J R Landers1
1Neuroscience Laboratory, Hugo Moser Research Institute at Kennedy Krieger, Baltimore, MD, USA.
Insights
ANA12, a TrkB antagonist, effectively treated phenobarbital-resistant neonatal seizures in mice by restoring KCC2 function. This offers a promising therapeutic strategy for refractory seizures in newborns.
Area of Science:
- Neuroscience
- Neonatal Neurology
- Pharmacology
Background:
- Neonatal seizures affect 3.5 per 1000 newborns, with hypoxic-ischemic encephalopathy (HIE) being a major cause.
- Half of HIE cases are resistant to first-line anti-seizure drugs like phenobarbital (PB).
- Tyrosine receptor kinase B (TrkB) activation post-ischemia increases neuronal excitability by downregulating K-Cl co-transporter 2 (KCC2).
Purpose of the Study:
- To evaluate the anti-seizure efficacy of ANA12, a selective TrkB antagonist, in neonatal ischemia models.
- To investigate ANA12's effects on KCC2 function and TrkB pathway activation following ischemia.
- To determine if ANA12 can rescue phenobarbital-resistant neonatal seizures.
Main Methods:
- Three doses of ANA12 were administered to CD1 mice at postnatal days 7 and 10 after inducing neonatal ischemia.
- Phenobarbital (PB) loading dose was kept constant across all groups.
- Efficacy was assessed via electroencephalography (EEG) seizure burden, KCC2/pKCC2-S940 levels, and TrkB pathway activation.
Main Results:
- ANA12 dose-dependently rescued PB-resistant seizures at P7 and improved PB efficacy at P10.
- ANA12 reversed post-ischemic KCC2 downregulation and TrkB pathway activation at P7, where PB was ineffective alone.
- Female pups showed a better response to lower ANA12 doses compared to males.
Conclusions:
- ANA12 demonstrates significant anti-seizure efficacy in neonatal ischemia, particularly for PB-resistant cases.
- Restoring KCC2 hypofunction via TrkB antagonism is a critical mechanism for preventing refractory neonatal seizures.
- ANA12 presents a potential therapeutic avenue for managing challenging neonatal seizure conditions.
Abstract:
Neonatal seizures have an incidence of 3.5 per 1000 newborns; while hypoxic-ischemic encephalopathy (HIE) accounts for 50-60% of cases, half are resistant to 1st-line anti-seizure drugs such as phenobarbital (PB). Tyrosine receptor kinase B (TrkB) activation following ischemic injury is known to increase neuronal excitability by downregulation of K-Cl co-transporter 2 (KCC2); a neuronal chloride (Cl-) co-transporter. In this study, three graded doses of ANA12, a small-molecule selective TrkB antagonist, were tested in CD1 mice at P7 and P10 following induction of neonatal ischemia by a unilateral carotid ligation. The PB loading dose remained the same in all treatment groups at both ages. Evaluation criteria for the anti-seizure efficacy of ANA12 were: (1) quantitative electroencephalographic (EEG) seizure burden and power, (2) rescue of post-ischemic KCC2 and pKCC2-S940 downregulation and (3) reversal of TrkB pathway activation following ischemia. ANA12 significantly rescued PB resistant seizures in a dose-dependent manner at P7 and improved PB efficacy at P10. Additionally, female pups responded better to lower doses of ANA12 compared to males. ANA12 significantly reversed post-ischemic KCC2 downregulation and TrkB pathway activation at P7 when PB alone was inefficacious. Rescuing KCC2 hypofunction may be critical for preventing emergence of refractory seizures.
Related Concept Videos
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Dose Size and Dosing Frequency: Determination Methods
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Frequency-dependent Selection
Resistivity

